Production Of GSK's Ziagen HIV Oral Liquid Medicine

A GlaxoSmithKline Canada Inc. employee bottles Ziagen, an HIV oral liquid medication, on the packaging line at the company's Canadian headquarters in Mississauga, Ontario, Canada, on Monday, Dec. 13, 2010. Global sales of existing HIV medicines will peak at $12 billion in 2012, then halve by 2019 as patent expiries increase competition from generic drugs, according to a report by Datamonitor Group earlier this year. Photographer: Norm Betts/Bloomberg via Getty Images
A GlaxoSmithKline Canada Inc. employee bottles Ziagen, an HIV oral liquid medication, on the packaging line at the company's Canadian headquarters in Mississauga, Ontario, Canada, on Monday, Dec. 13, 2010. Global sales of existing HIV medicines will peak at $12 billion in 2012, then halve by 2019 as patent expiries increase competition from generic drugs, according to a report by Datamonitor Group earlier this year. Photographer: Norm Betts/Bloomberg via Getty Images
Production Of GSK's Ziagen HIV Oral Liquid Medicine
PURCHASE A LICENCE
How can I use this image?
AED 1,850.00
AED

DETAILS

Restrictions:
Contact your local office for all commercial or promotional uses.For editorial use only. Additional clearance required for commercial or promotional use, contact your local office for assistance. Any commercial or promotional use of Bloomberg content requires Bloomberg's prior written consent.
Credit:
Bloomberg / Contributor
Editorial #:
107630288
Collection:
Bloomberg
Date created:
13 December, 2010
Upload date:
Licence type:
Release info:
Not released. More information
Source:
Bloomberg
Object name:
GLAXO
Max file size:
2963 x 1975 px (25.09 x 16.72 cm) - 300 dpi - 2 MB